Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503178
Status:
COMPLETED
Last Update Posted:
2022-12-22
First Post:
2007-07-17
Brief Title:
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases Phase II Trial
Sponsor:
University Hospital Ghent
Organization:
University Hospital Ghent
Study Overview
Official Title:
Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases Phase II Trial
Status:
COMPLETED
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Highly selective irradiation requires accurate target definition by high-resolution three-dimensional imaging Co-registration of FDG-PET and high-resolution CT might be the imaging modality of choice This choice might target radiation therapy precisely to the intra-osseous volume that is responsible for pain and to spare selectively healthy bone in the vicinity of the metastasis This strategy could result in equal anti-pain efficacy as conventional large volume radiotherapy but could allow bone remodeling and preservation of bone structural strength in the vicinity and could lead to reduced toxicity to neighboring organs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None